EPHA2 and mesothelioma: This approach has since been widely applied to a range of preclinical mouse models to treat, for example, mesothelioma coexpressing ALPPL2 and MCAM antigens (ALPPL2-SynNotch and MCAM-CAR) or glioblastoma expressing either EphA2 or IL13Ra2 present in the vicinity of EGFRvIII+ tumor cells (SynNotch-EGFRvIII and EphA2.IL13Ra2 Tan-CAR; refs. 98, 99).